{"id":"W2947633439","doi":"10.1200/jco.2019.37.15_suppl.5518","title":"A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":21,"is_retracted":false,"has_abstract":true,"ca_institutions":"Cancer Care Ontario; BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Oncology; Olaparib; BRCA mutation; Ovarian cancer; Cancer; Progression-free survival; Placebo; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002028632,0.002220749,0.003200377,0.0005957848,0.0005896545,0.00111356,0.001072634,0.002467707,0.009018208],"category_scores_gemma":[0.002036785,0.001112034,0.001491671,0.0004935047,0.001640502,0.001204695,0.0005369679,0.002897685,0.00156514],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008467449,"about_ca_system_score_gemma":0.001664851,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008989183,"about_ca_topic_score_gemma":0.002849994,"domain_scores_codex":[0.9991934,0.0004517279,0.00004699087,0.0001703752,0.00004145205,0.00009607287],"domain_scores_gemma":[0.9989731,0.0002300924,0.0002535094,0.0000924225,0.00006452051,0.0003862861],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9848942,0.006423023,0.000211759,0.0003108571,0.0003195588,0.00001679645,0.00002778138,0.0001245709,0.001849155,0.00005429254,0.0004856524,0.005282208],"study_design_scores_gemma":[0.9605952,0.03831838,0.0004060081,0.00001110637,0.0001096752,0.000007789747,0.0000075769,0.0001173246,0.0001064896,0.00005579926,0.0002592486,0.000005367649],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9616096,0.005668469,0.001272056,0.001810519,0.001610999,0.02158784,0.00244561,0.0003340135,0.003660877],"genre_scores_gemma":[0.9585074,0.003011889,0.003426087,0.002590006,0.0008081919,0.02214047,0.001821817,0.0000513162,0.007642971],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009018208,"threshold_uncertainty_score":0.03016895,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04141560706164391,"score_gpt":0.3808206048477158,"score_spread":0.3394049977860719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}